JY
FBLG icon

Jeff Yass’s FibroBiologics FBLG Stock Holding History

Jeff Yass’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,305
Closed -$66K – 14110
2025
Q2 		$66K Buy
5,305
+3,545
+201% +$63.9K ﹤0.01% 12015
2025
Q1 		$31.7K Buy
1,760
+1,113
+172% +$31.8K ﹤0.01% 11991
2024
Q4 		$25.9K Buy
+647
New +$34.7K ﹤0.01% 11869

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's FBLG Position: Q3 2025 in Review

Jeff Yass sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 5,305 shares — an estimated $66K sold.

Jeff Yass first reported a position in FBLG in Q4 2024 and held it in 3 quarters. The position peaked at $66K in Q2 2025. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

  • Jeff Yass reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
  • Jeff Yass sold 5,305 FibroBiologics shares in Q3 2025, an estimated $66K.
  • Jeff Yass first reported a position in FibroBiologics in Q4 2024 and held it in 3 quarters.
  • Jeff Yass's FibroBiologics position peaked at $66K in Q2 2025.
  • 52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.